Edwards Lifesciences (NYSE: EW) CVP logs sale and major equity awards

Rhea-AI Filing Summary

Edwards Lifesciences Corp executive Wayne Markowitz, CVP, JAPAC, reported a mix of share sales and new equity awards. He completed an open-market sale of 593 shares of common stock at $79.73 per share on May 11, 2026, and held 21,679.8708 shares afterward.

On May 7, 2026, he received 5,200 restricted stock units and separate 5,200 performance-based restricted stock units under the Long-Term Stock Incentive Compensation Program, plus 26,400 employee stock options with a $82.76 exercise price, all vesting in installments starting one year after grant.

On May 7 and May 8, a total of 490 shares of common stock were disposed of as tax-withholding transactions related to equity compensation, rather than open-market sales.

Insider Trade Summary

Net Seller: 593 shares ($47,280)

Net Sell 6 txns

Insider Markowitz Wayne

Role CVP, JAPAC

Sold 593 shs ($47K)

Type	Security	Shares	Price	Value
Sale	Common Stock	593	$79.73	$47K
Tax Withholding	Common Stock	226	$82.76	$19K
Grant/Award	Employee Stock Option (Right to Acquire)	26,400	$0.00	--
Grant/Award	Performance Rights	5,200	$0.00	--
Grant/Award	Common Stock	5,200	$0.00	--
Tax Withholding	Common Stock	264	$83.20	$22K

Holdings After Transaction: Common Stock — 21,679.871 shares (Direct, null); Employee Stock Option (Right to Acquire) — 26,400 shares (Direct, null); Performance Rights — 5,200 shares (Direct, null)

Footnotes (1)

1. These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.

Key Figures

Open-market sale: 593 shares at $79.73 Post-transaction holdings: 21,679.8708 shares Restricted stock units granted: 5,200 shares +3 more

6 metrics

Open-market sale 593 shares at $79.73 Common stock sale on May 11, 2026

Post-transaction holdings 21,679.8708 shares Common stock directly held after May 11, 2026 sale

Restricted stock units granted 5,200 shares Time-based RSUs granted May 7, 2026

Performance RSU target award 5,200 shares, 0–200% possible Vests May 7, 2029 based on three-year goals

Stock options granted 26,400 options at $82.76 Employee stock options granted May 7, 2026, expire 2033

Tax-withholding shares 490 shares Shares disposed for tax obligations May 7–8, 2026

Key Terms

restricted stock units, Long-Term Stock Incentive Compensation Program, Performance Rights, Employee Stock Option (Right to Acquire), +2 more

6 terms

restricted stock units financial

"These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Long-Term Stock Incentive Compensation Program financial

"granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program"

Performance Rights financial

"security_title":"Performance Rights","transaction_date":"2026-05-07T00:00:00.000Z""

Performance rights are conditional awards that give employees or executives the promise of receiving company shares or cash only if the business meets specific targets or survives for a set period. They work like a bonus you only get when certain goals are hit, so they matter to investors because they can increase the number of shares outstanding (dilution), signal management’s incentives and confidence in future results, and affect per-share earnings and valuation.

Employee Stock Option (Right to Acquire) financial

"security_title":"Employee Stock Option (Right to Acquire)","transaction_date":"2026-05-07T00:00:00.000Z""

tax-withholding disposition financial

"transaction_action":"tax-withholding disposition","transaction_code_description":"Payment of exercise price or tax liability by delivering securities""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Target Award financial

"Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Markowitz Wayne

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, JAPAC

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/07/2026		A		5,200(1)	A	$0.0000	22,762.8708	D
Common Stock	05/07/2026		F		264	D	$83.2	22,498.8708	D
Common Stock	05/08/2026		F		226	D	$82.76	22,272.8708	D
Common Stock	05/11/2026		S		593	D	$79.73	21,679.8708	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Acquire)	$82.76	05/07/2026		A		26,400		05/07/2027(2)	05/06/2033	Common Stock	26,400	$0.0000	26,400	D
Performance Rights	(3)	05/07/2026		A		5,200		05/07/2029	(3)	Common Stock	5,200	$0.0000	5,200	D

Explanation of Responses:

1. These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

2. These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

3. Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Edwards Lifesciences (EW) report for Wayne Markowitz?

Wayne Markowitz reported an open-market sale of 593 common shares and several equity awards. He also had tax-withholding dispositions tied to compensation. After these transactions, he directly held 21,679.8708 shares of Edwards Lifesciences common stock.

How many Edwards Lifesciences (EW) shares did Wayne Markowitz sell and at what price?

Wayne Markowitz sold 593 shares of Edwards Lifesciences common stock at $79.73 per share. This was reported as an open-market sale, and it reduced but did not eliminate his direct shareholding in the company following the transaction.

What new equity awards did Wayne Markowitz receive from Edwards Lifesciences (EW)?

He received 5,200 restricted stock units, 5,200 performance-based restricted stock units, and 26,400 employee stock options with an $82.76 exercise price. These awards were granted under the company’s Long-Term Stock Incentive Compensation Program on May 7, 2026.

How do the performance-based restricted stock units for Edwards Lifesciences (EW) work?

The performance-based restricted stock units reflect a target 5,200-share award scheduled to vest on May 7, 2029. Actual vesting will depend on achieving three-year performance goals, and the payout can range from 0% to 200% of the target number of units.

Were any of Wayne Markowitz’s Edwards Lifesciences (EW) transactions related to taxes?

Yes. On May 7 and May 8, 2026, a total of 490 shares were disposed of in tax-withholding transactions. These were used to satisfy tax obligations on equity compensation, rather than representing open-market sales of shares.

What stock option grant did Wayne Markowitz receive from Edwards Lifesciences (EW)?

He was granted 26,400 employee stock options on May 7, 2026 with an exercise price of $82.76 per share. These options vest and become exercisable in four equal annual installments, beginning one year after the grant date and expiring in 2033.